According to our research, most patients discontinue treatment before 12 weeks, yet the financial impact remains significant
They can include combinations of anti-inflammatory medications, muscle relaxants, neuropathic agents, and anesthetics
Apitegromab was generally well tolerated, with adverse events comparable between groups and no serious safety events attributed to the treatment
Virginia Medicaid changed criteria, limiting coverage to individuals with a body mass index (BMI) greater than 40 or those with a BMI greater than 37 with weight-related comorbidities (defined as hypertension, type 2 diabetes, or dyslipidemia) effective July 1, 2024
Tirzepatide: Recent studies indicate mean weight loss of 1620% at 1 year, with some head-to-head trials showing greater absolute reductions compared to semaglutide
and thyroid function tests to exclude anemia, renal disease, and electrolyte or thyroid disorders